4 Artificial Intelligence Stocks (That Aren't Nvidia) You Can Buy and Hold for the Next Decade
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 29 2025
0mins
Should l Buy AURA?
Source: NASDAQ.COM
Meta Platforms and AI Development: Meta is utilizing its vast user base to innovate and test new AI products, investing heavily in the future while maintaining strong financial performance with significant cash flow.
Opportunities in Autonomous Vehicles and Cloud Services: Amazon's AWS is thriving amidst the AI boom, while Uber and Aurora Innovations are strategically positioned in the autonomous vehicle market, focusing on partnerships and technology development respectively.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AURA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AURA
Wall Street analysts forecast AURA stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 6.270
Low
13.00
Averages
19.33
High
23.00
Current: 6.270
Low
13.00
Averages
19.33
High
23.00
About AURA
Aura Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors that aim to preserve organ function. The Company’s lead candidate, bel-sar (AU-011), is in late-stage development for primary choroidal melanoma and in early-stage development in other ocular oncology indications and bladder cancer. It is developing bel-sar as a potential first-line vision-sparing treatment option for early intervention in small choroidal melanoma and/or indeterminate lesions, avoiding the need for radiotherapy and reducing the risk for metastasis for these patients. Bel-sar is a virus-like drug conjugate (VDC) consisting of a human papillomavirus (HPV)-derived virus-like particle (VLP) and a phthalocyanine dye, a light-activated cytotoxic payload. The Company’s platform is designed to enable the targeting of a broad range of solid tumors using VLP, that can be conjugated with drugs or loaded with nucleic acids to create VDCs.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Aura Biosciences Reports FY EPS Beat
- Earnings Performance: Aura Biosciences reported a fiscal year GAAP EPS of -$1.76, beating expectations by $0.19, indicating improvements in financial management despite remaining in a loss position.
- Cash Reserves: As of December 31, 2025, the company had cash and cash equivalents and marketable securities totaling $144.2 million, ensuring financial stability for future operations.
- Sufficient Funding: Aura believes its current cash and cash equivalents and marketable securities are adequate to fund operations into the first quarter of 2027, reflecting confidence in future growth.
- Market Reaction: Following the earnings release, market interest in Aura Biosciences has increased, and investor expectations regarding its growth potential may influence stock price movements.
See More
AURA BIOSCIENCES ANNOUNCES FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS FOR FOURTH QUARTER AND FULL YEAR 2025
Financial Results Overview: AURA Biosciences has reported its financial results for the fourth quarter and the full year of 2025, highlighting key performance metrics and financial health.
Business Highlights: The report includes significant business developments and achievements that occurred throughout the year, showcasing the company's growth and strategic initiatives.
See More
AURA BIOSCIENCES Reports FY Operating Loss of USD 112.791 Million
- Operating Income: AURABIOSCIENCES reported an operating income of USD 112.791 million.
- Financial Performance: The financial results indicate a significant performance in the company's operations.
See More
BETA Technologies Reports Disappointing Q4 Results
- Earnings Miss: BETA Technologies reported a Q4 loss of $2.02 per share, significantly worse than the analyst consensus estimate of a loss of $0.84, indicating substantial challenges in profitability that could undermine investor confidence.
- Sales Beat: Despite the significant losses, the company achieved quarterly sales of $11.133 million, surpassing the analyst consensus of $7.859 million, suggesting some resilience in market demand that could lay the groundwork for future growth.
- Stock Reaction: In pre-market trading, BETA's shares fell 3.1% to $18.67, reflecting a negative investor response to the earnings report, which may lead to increased liquidity pressure in the short term.
- Market Sentiment: The overall market sentiment is bearish, with Dow futures down over 1%, indicating investor concerns about the economic outlook, which could further impact BETA Technologies and other related stocks.
See More
Lisata Therapeutics to be Taken Private by Kuva Labs
- Acquisition Agreement: Lisata Therapeutics Inc has agreed to be taken private by Kuva Labs, offering shareholders $5.00 per share along with a $1.00 contingent value right per share, indicating recognition of the company's future potential.
- Significant Stock Surge: Following the acquisition announcement, Lisata Therapeutics' shares rose 20.3% in pre-market trading to $5.03, reflecting positive market reaction and increased investor confidence in the deal.
- Impact of Privatization: The acquisition will result in Lisata Therapeutics delisting from public markets, potentially providing the company with greater flexibility to focus on long-term strategic goals while mitigating the impact of market volatility on its operations.
- Market Dynamics Shift: The announcement of this deal has sparked interest in other related stocks, demonstrating investor enthusiasm for M&A activity in the biotech sector, which may influence future investment decisions and market trends.
See More
WhiteFiber Inc (WYFI) Announces $200 Million Convertible Notes Offering, Shares Drop 5.5%
- Convertible Notes Offering: WhiteFiber Inc announced a $200 million convertible notes offering, resulting in a 5.5% drop in its share price during pre-market trading, which may negatively impact investor confidence and future financing capabilities.
- Market Reaction: Following the convertible notes announcement, WhiteFiber's stock fell to $19.19 in pre-market trading, reflecting market concerns over the company's financial health and potentially affecting shareholder returns.
- Other Stock Movements: Caleres, Inc. shares tumbled 8.6% in pre-market trading after naming Dan Karpel as interim CFO, indicating that changes in corporate governance may impact its market performance.
- Overall Industry Trends: Aura Biosciences Inc shares dipped 7%, while GoldMining Inc and T1 Energy Inc fell 5.5% and 5.4% respectively, suggesting a general downturn in market sentiment that could affect investor confidence across related sectors.
See More
Aura Biosciences Reports FY EPS Beat
- Earnings Performance: Aura Biosciences reported a fiscal year GAAP EPS of -$1.76, beating expectations by $0.19, indicating improvements in financial management despite remaining in a loss position.
- Cash Reserves: As of December 31, 2025, the company had cash and cash equivalents and marketable securities totaling $144.2 million, ensuring financial stability for future operations.
- Sufficient Funding: Aura believes its current cash and cash equivalents and marketable securities are adequate to fund operations into the first quarter of 2027, reflecting confidence in future growth.
- Market Reaction: Following the earnings release, market interest in Aura Biosciences has increased, and investor expectations regarding its growth potential may influence stock price movements.
See More
AURA BIOSCIENCES ANNOUNCES FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS FOR FOURTH QUARTER AND FULL YEAR 2025
Financial Results Overview: AURA Biosciences has reported its financial results for the fourth quarter and the full year of 2025, highlighting key performance metrics and financial health.
Business Highlights: The report includes significant business developments and achievements that occurred throughout the year, showcasing the company's growth and strategic initiatives.
See More
AURA BIOSCIENCES Reports FY Operating Loss of USD 112.791 Million
- Operating Income: AURABIOSCIENCES reported an operating income of USD 112.791 million.
- Financial Performance: The financial results indicate a significant performance in the company's operations.
See More
BETA Technologies Reports Disappointing Q4 Results
- Earnings Miss: BETA Technologies reported a Q4 loss of $2.02 per share, significantly worse than the analyst consensus estimate of a loss of $0.84, indicating substantial challenges in profitability that could undermine investor confidence.
- Sales Beat: Despite the significant losses, the company achieved quarterly sales of $11.133 million, surpassing the analyst consensus of $7.859 million, suggesting some resilience in market demand that could lay the groundwork for future growth.
- Stock Reaction: In pre-market trading, BETA's shares fell 3.1% to $18.67, reflecting a negative investor response to the earnings report, which may lead to increased liquidity pressure in the short term.
- Market Sentiment: The overall market sentiment is bearish, with Dow futures down over 1%, indicating investor concerns about the economic outlook, which could further impact BETA Technologies and other related stocks.
See More
Lisata Therapeutics to be Taken Private by Kuva Labs
- Acquisition Agreement: Lisata Therapeutics Inc has agreed to be taken private by Kuva Labs, offering shareholders $5.00 per share along with a $1.00 contingent value right per share, indicating recognition of the company's future potential.
- Significant Stock Surge: Following the acquisition announcement, Lisata Therapeutics' shares rose 20.3% in pre-market trading to $5.03, reflecting positive market reaction and increased investor confidence in the deal.
- Impact of Privatization: The acquisition will result in Lisata Therapeutics delisting from public markets, potentially providing the company with greater flexibility to focus on long-term strategic goals while mitigating the impact of market volatility on its operations.
- Market Dynamics Shift: The announcement of this deal has sparked interest in other related stocks, demonstrating investor enthusiasm for M&A activity in the biotech sector, which may influence future investment decisions and market trends.
See More
WhiteFiber Inc (WYFI) Announces $200 Million Convertible Notes Offering, Shares Drop 5.5%
- Convertible Notes Offering: WhiteFiber Inc announced a $200 million convertible notes offering, resulting in a 5.5% drop in its share price during pre-market trading, which may negatively impact investor confidence and future financing capabilities.
- Market Reaction: Following the convertible notes announcement, WhiteFiber's stock fell to $19.19 in pre-market trading, reflecting market concerns over the company's financial health and potentially affecting shareholder returns.
- Other Stock Movements: Caleres, Inc. shares tumbled 8.6% in pre-market trading after naming Dan Karpel as interim CFO, indicating that changes in corporate governance may impact its market performance.
- Overall Industry Trends: Aura Biosciences Inc shares dipped 7%, while GoldMining Inc and T1 Energy Inc fell 5.5% and 5.4% respectively, suggesting a general downturn in market sentiment that could affect investor confidence across related sectors.
See More
